GlassScriptPhysician profile
Luis J Acosta
NPI 1720106966
$2,862.47
in general payments reported to CMS, 2019-2025
26 companies · $416 in 2025
The $416 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $14.08 · 2021: $161 · 2022: $681 · 2023: $419 · 2024: $945 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255 · Consulting Fee: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,254.60 |
| Consulting Fee | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $695.70 | 2021-2025 | Mavyret, Rinvoq |
| Daiichi Sankyo INC. | $525.00 | 2024 | Enhertu |
| Pfizer INC. | $155.09 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.36 | 2019-2024 | Trulance |
| Genzyme Corporation | $145.41 | 2023-2025 | |
| Madrigal Pharmaceuticals | $133.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Olympus America INC. | $121.12 | 2022 | |
| Boston Scientific Corporation | $117.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.97 | 2022-2023 | Entyvio |
| Gilead Sciences, INC. | $97.88 | 2024-2025 | Epclusa |
| Merck Sharp & Dohme LLC | $97.43 | 2023-2024 | Dificid |
| Celgene Corporation | $77.02 | 2022-2023 | |
| Novo Nordisk INC | $69.41 | 2021 | |
| Qol Medical, LLC | $62.00 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $50.45 | 2025 | Dysport, Iqirvo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $42.17 | 2025 | Tremfya |
| Braintree Laboratories, INC. | $32.53 | 2022 | |
| Ferring Pharmaceuticals INC. | $31.05 | 2023 | Rebyota |
| Aimmune Therapeutics, INC. | $23.79 | 2024 | |
| Alexion Pharmaceuticals, INC. | $22.85 | 2022 | |
| Nestle Healthcare Nutrition INC. | $22.15 | 2023 | |
| La Jolla Pharmaceutical Company | $21.49 | 2024 | Xerava |
| Organon LLC | $18.83 | 2023 | Hadlima |
| Convatec INC. | $14.94 | 2024 | |
| Supernus Pharmaceuticals, INC. | $14.08 | 2020 | |
| Intercept Pharmaceuticals, INC. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Acosta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.